CompletedPhase 4

Prevention of Cefoperazone-induced Coagulopathy

Egypt56 participantsStarted 2023-02-25

Plain-language summary

Evaluating the effect of prophylactic doses of vitamin K in preventing the adverse effect of cefoperazone/sulbactam induced coagulopathy in critically ill patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ICU admitted patients on treatment or prophylactic doses of cefoperazone/sulbactam. Exclusion Criteria: * Patients' aged \<18 years * Pregnancy or breastfeeding women * Active bleeding or bleeding disorder * Patients having an abnormal baseline coagulation profile. * Patients administer total parenteral nutrition with regular vitamin k supplements. * Refusal to sign the written informed consent.

What they're measuring

Number of Participants with changes in INR level

Timeframe: During the duration of cefoperazone/sulbactam treatment up to 2 weeks

Trial details

NCT IDNCT05742295

SponsorHelwan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-10-05

View on ClinicalTrials.gov More Antibiotic Side Effect trials